LDC-backed Aescia completes European acquisitions
LDC-backed Aesica Pharmaceuticals has successfully completed the acquisition of three manufacturing sites in Germany and Italy from leading biopharma company, UCB. Aesica was formed in September 2004 through a management buyout of a former BASF site in Cramlington, Northumberland, backed by LDC, which took a significant stake in the business

